5Andrs RPR,Augusto HU,Celso F,et al.Relationship among amiod-arone,new class III antiarrhythmics,miscellaneous agents and ac-quired long QT syndrome. Cardiology Journal . 2008
2Gowda RM, Punukotlu G, Khan IA, et al. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety. Am J Ther,2003,10:259-263.
3Antonicelli R, Testarmata P, Recanatini A. lbutilide in rapid conversion of atrial flutter in octogenarians. Drugs Aging, 2002, 19:787-791.
4Gowda RM, Punukollu G, Khan IA, et al. lbutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety. Am J Ther, 2003, 10: 259-263.
5Cheng J, Glatter K, Yang Y, et al. Electrophysiological response of the right atrium to ibutilide during typical atrial flutter. Circulation, 2002,106:814-819.
6Kafkas NV, Patsilinakos SP, Mertzanos GA,et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodalone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol,2007 ,118 :321-325.
7Eidher U, Freihoff F, Kaltenbrunner W, el al. Efficacy and safety of ibutilide for the conversion of monomorphic atrial tachycardia. Pacing Clin Electrophysiol, 2006,29 : 358-362.
8Hongo RH, Themistoclakis S, Raviele A, et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol,2004,4d-:86d-- 868.
9Rodriguez I, Kilbom MJ, Liu XK,et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA,2001, 285 : 1322-1326.
10Kowey PR, Vanderlugt JT, Luderer JR. Safety and risk /benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol, 1996,78: 46-52.
